The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that it is best to focus on “commercial-stage or regulatory-stage companies with substantial cash reserves” at ...
The shares of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) currently has mean rating of 2.71 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 5 recommended as “HOLD”.
MRS371 “Arena Pharmaceuticals, Inc. Global 2015 Clinical Trials Review, H2” provides an detailed overview of Arena Pharmaceuticals, Inc. scenario. Report includes top line data relating on Arena Pharmaceuticals, Inc. Global clinical trials scenario.
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, ARN reports.